Implantation of a second closure device in patients with residual shunt after percutaneous closure of patent foramen ovale

被引:30
作者
Schwerzmann, M
Windecker, S
Wahl, A
Nedeltchev, K
Mattle, HP
Seiler, C
Meier, B [1 ]
机构
[1] Univ Hosp Bern, Swiss Cardiovasc Ctr Bern, Dept Neurol, CH-3010 Bern, Switzerland
[2] Swiss Cardiovasc Ctr Bern, CH-3010 Bern, Switzerland
关键词
patent foramen ovale; cryptogenic stroke; percutaneous intervention;
D O I
10.1002/ccd.20221
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Percutaneous closure of patent foramen ovale (PFO) in patients with presumed paradoxical embolism yields complete occlusion in > 90% of patients using contemporary closure devices. Patients with a residual shunt after percutaneous PFO closure have been found at increased risk for recurrent paradoxical events. Treatment options for such patients include medical treatment using antiplatelet drugs or oral anticoagulation, surgical device removal and patch closure, and percutaneous implantation of a second closure device. We report our experience with implantation of a second closure device in 10 patients with more than a minimal residual shunt :5 6 months after percutaneous PFO closure. Procedure and fluoroscopy times were similar for the initial and repeat intervention (32 vs. 30 min and 5 vs. 6 min, respectively; P = NS). There were no procedural complications during implantation of the second closure device. Follow-up transesophageal echocardiography 6 months after the second percutaneous intervention revealed complete PFO closure in nine (90%) patients. Therefore, implantation of a second closure device in patients with persistence of more than a residual shunt after percutaneous PFO closure appears safe and effective. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:490 / 495
页数:6
相关论文
共 15 条
[1]   Is testing for inherited coagulation inhibitor deficiencies in young stroke patients worthwhile? [J].
Amiri, M ;
Schmidley, JW ;
Fink, LM ;
Nazarian, SM .
CLINICAL NEUROLOGY AND NEUROSURGERY, 2000, 102 (04) :219-222
[2]   Antiphospholipid antibodies in the acute phase of cerebral ischaemia in young adults: A descriptive study of 139 patients [J].
Blohorn, A ;
Guegan-Massardier, E ;
Triquenot, A ;
Onnient, Y ;
Tron, F ;
Borg, JY ;
Mihout, B .
CEREBROVASCULAR DISEASES, 2002, 13 (03) :156-162
[3]   Prevention of stroke recurrence with presumed paradoxical embolism [J].
Bogousslavsky, J ;
Devuyst, G ;
Nendaz, M ;
Yamamoto, H ;
Sarasin, F .
JOURNAL OF NEUROLOGY, 1997, 244 (02) :71-75
[4]   Transcatheter closure of patent foramen ovale in patients with cerebral ischemia [J].
Braun, MU ;
Fassbender, D ;
Schoen, SP ;
Haass, M ;
Schraeder, R ;
Scholtz, W ;
Strasser, RH .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (12) :2019-2025
[5]   TRANSCATHETER CLOSURE OF PATENT FORAMEN OVALE AFTER PRESUMED PARADOXICAL EMBOLISM [J].
BRIDGES, ND ;
HELLENBRAND, W ;
LATSON, L ;
FILIANO, J ;
NEWBURGER, JW ;
LOCK, JE .
CIRCULATION, 1992, 86 (06) :1902-1908
[6]   Transcatheter closure of interatrial communications for secondary prevention of paradoxical embolism - Single-center experience [J].
Bruch, L ;
Parsi, A ;
Grad, MO ;
Rux, S ;
Burmeister, T ;
Krebs, H ;
Kleber, FX .
CIRCULATION, 2002, 105 (24) :2845-2848
[7]   PREVALENCE OF PATENT FORAMEN OVALE IN PATIENTS WITH STROKE [J].
LECHAT, P ;
MAS, JL ;
LASCAULT, G ;
LORON, P ;
THEARD, M ;
KLIMCZAC, M ;
DROBINSKI, G ;
THOMAS, D ;
GROSGOGEAT, Y .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (18) :1148-1152
[8]   Pacman Sign during device closure of the patent foramen ovale [J].
Meier, B .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2003, 60 (02) :221-223
[9]   Contemporary management of patent foramen ovale [J].
Meier, B ;
Lock, JE .
CIRCULATION, 2003, 107 (01) :5-9
[10]   Interatrial septal abnormalities and stroke - A meta-analysis of case-control studies [J].
Overell, JR ;
Bone, I ;
Lees, KR .
NEUROLOGY, 2000, 55 (08) :1172-1179